KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation ...
Strategic agreement broadens Xanadu’s presence in SingaporeTORONTO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Xanadu Quantum Technologies Inc. (“Xanadu”), a leading photonic quantum computing company, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback